Lori Boyce and Michael Lydon on FSP outsourcing trends

#IQVIA contract sales organization (CSO) experts, Kirk Harmon and Javier "Jave" Castillo, share four reasons to take a fresh look at CSOs as biopharma organizations continue to navigate changing business fundamentals. The CSO model offers compelling value in the form of lower fixed costs, greater operational agility, and access to top-tier talent and technologies. Learn more now: https://bit.ly/3Kd3Y4L

🚨 𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗦𝗖𝗜𝗘𝗫 𝗹𝗮𝘁𝗲𝘀𝘁 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝘁 #ASMS2024 To make data-driven, business-critical decisions, you need an instrument that can give you high-quality data, flexibility, and speed. #TeamSCIEX is looking forward to seeing you all at ASMS. Stop by booth no. 402 and don't miss our #BreakfastSeminars to learn about how the Echo® MS+ system could help you make the right decision today. 👉 https://bit.ly/3wfetkK 𝗡𝗼𝘁 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗔𝗦𝗠𝗦 𝘁𝗵𝗶𝘀 𝘆𝗲𝗮𝗿? Learn more here 👉 https://bit.ly/3SHeJ4I #Pharma #PharmaDiscovery #AcousticDropletEjection #ADE #OpenPortInterface #OPI #AcousticEjectionMassSpectrometry #AEMS #MassSpectrometry #HighThroughputScreening #HighThroughputWorkflows #EchoMSPlus #IntegratedSolutions #ProductLaunch #Innovation

"Together, apexanalytix and the company have delivered more than $800M to the bottom line through the mitigation of duplicate payments and through a continuous audit model that enables apex to work closer to the transaction, identifying overpayments for recovery earlier." After a 305% increase in overpayments over the course of a year, this pharma giant decided enough was enough. Learn how they now protect themselves from overpayments with timely recovery audit and strong duplicate prevention controls. Read the full case study here: https://lnkd.in/ehDg6x-E

How do your fill rates compare to industry standards? #ClaritasRx #fillrates #rarediseaae #oncology #benchmarking #dataaggregation

"Together, apexanalytix and the company have delivered more than $800M to the bottom line through the mitigation of duplicate payments and through a continuous audit model that enables apex to work closer to the transaction, identifying overpayments for recovery earlier." After a 305% increase in overpayments over the course of a year, this pharma giant decided enough was enough. Learn how they now protect themselves from overpayments with timely recovery audit and strong duplicate prevention controls. Read the full case study here: https://lnkd.in/d85a2yxy

Unleash the full potential of your biopharma asset with Corval's domain-driven platform. Our deep industry knowledge guides you through critical decision points, optimizing timelines and resource allocation. By mitigating risks and maximizing opportunities, we empower you to achieve commercial success. https://hubs.la/Q02KdbWT0

Curious about how your therapy basket's fill rate stacks up? 📊 Claritas Rx uses exclusive data to provide biopharma executives with competitive insights. Understand how your treatment's fill rate measures up against the competition and stay ahead in the industry: https://hubs.li/Q02FXN8q0 Interested in a free metrics perspective of your therapy basket? Claim Your Free Metrics Now! ⬇️ https://lnkd.in/g9_Y_Pbx #Biopharma #CompetitiveInsights

💊 Adverse drug interactions are a major cause of preventable patient harm. To address this, clinicians need reliable tools backed by the latest evidence to support safe, informed decisions. DynaMedex® offers access to the trusted Drug Interactions Checker from Micromedex, helping clinicians identify and manage potential drug interactions with confidence. From dosage adjustments to alternative therapies, it provides the guidance necessary to help protect patients and improve outcomes. Learn more about #DynaMedex: https://lnkd.in/gJyBiy3T #ClinicalDecisionSupport #Micromedex #EvidenceBasedMedicine #PreventableHarm #DrugInteractions

BENLYSTA (belimumab) is a specific inhibitor of B-lymphocyte stimulator, was initially approved in 2011 for adults with SLE receiving standard therapy. Recently, in 2024, it gained US FDA approval for a 200 mg subcutaneous autoinjector for patients aged five years and older with active SLE. According to DelveInsight Business Research LLP, BENLYSTA is projected to achieve approximately USD 980 million in sales by 2034 in the US. However, sales are expected to decrease after 2025 due to the drug's patent expiration in the United States in 2025 and in Europe in 2026. Discover Expert Insights and Comprehensive Analysis with DelveInsight's Exclusive EULAR - European Alliance of Associations for Rheumatology 2024 Coverage @ https://lnkd.in/gBpFeusS #BENLYSTA #SLE #belimumab #FDAapproval #autoinjector #chronicillness #SLEtreatment #autoimmune #pharmaceuticals #patentexpiration